Description
Treatment for H. pylori infection must be tailored to local resistance patterns, with quadruple and guided regimens becoming increasingly important as resistance rises.
Standard triple therapy (PPI + clarithromycin + amoxicillin/metronidazole) remains viable in areas with <15% clarithromycin resistance, ideally for 14 days.
Non-bismuth quadruple regimens (sequential, concomitant, hybrid) are effective alternatives, especially where resistance is higher.
Emerging options include vonoprazan-based therapy, showing promise against resistant strains.